Blockchain Registration Transaction Record

Oncotelic Targets Brain Delivery with Nose-to-Brain Platform

Oncotelic Therapeutics advances nose-to-brain delivery platform for Alzheimer's and biodefense, partnering with Biogen, Moderna, and others to overcome blood-brain barrier challenges.

This news is important because it highlights a potential breakthrough in drug delivery to the brain, a major hurdle in treating neurological diseases like Alzheimer's and in biodefense. If successful, Oncotelic's platform could enable more effective therapies for millions of patients worldwide, addressing a critical unmet need. The approach also underscores the growing importance of delivery technologies in the pharmaceutical industry, which could reshape treatment paradigms and investment opportunities.